Published in Breast Cancer Res Treat on February 13, 2007
Hedgehog signaling in the liver. J Hepatol (2010) 1.80
Development of mammary tumors by conditional expression of GLI1. Cancer Res (2009) 1.30
Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res Treat (2008) 1.27
Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma. Mol Cancer (2008) 1.20
Hedgehog signalling in breast cancer. Carcinogenesis (2009) 1.18
Assessing combined methylation-sensitive high resolution melting and pyrosequencing for the analysis of heterogeneous DNA methylation. Epigenetics (2011) 1.12
Krüppel-like factor 9 and progesterone receptor coregulation of decidualizing endometrial stromal cells: implications for the pathogenesis of endometriosis. J Clin Endocrinol Metab (2012) 1.08
The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. Breast Cancer Res (2013) 1.01
miR-212 promotes pancreatic cancer cell growth and invasion by targeting the hedgehog signaling pathway receptor patched-1. J Exp Clin Cancer Res (2014) 0.98
Implications of hedgehog signaling antagonists for cancer therapy. Acta Biochim Biophys Sin (Shanghai) (2008) 0.92
Shared signaling pathways in normal and breast cancer stem cells. J Carcinog (2011) 0.91
Gli1 promotes cell survival and is predictive of a poor outcome in ERalpha-negative breast cancer. Breast Cancer Res Treat (2009) 0.91
Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapy. Expert Rev Mol Med (2015) 0.87
Detection and analysis of the methylation status of PTCH1 gene involved in the hedgehog signaling pathway in a human gastric cancer cell line. Exp Ther Med (2013) 0.84
Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells. Mol Cancer (2015) 0.82
A seven-gene CpG-island methylation panel predicts breast cancer progression. BMC Cancer (2015) 0.82
The Potential Role of Hedgehog Signaling in the Luminal/Basal Phenotype of Breast Epithelia and in Breast Cancer Invasion and Metastasis. Cancers (Basel) (2015) 0.81
Combination of cyclopamine and tamoxifen promotes survival and migration of mcf-7 breast cancer cells--interaction of hedgehog-gli and estrogen receptor signaling pathways. PLoS One (2014) 0.81
Mammary development and breast cancer: the role of stem cells. Curr Mol Med (2011) 0.80
In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. Oncotarget (2016) 0.80
Epigenetic heredity of human height. Physiol Rep (2014) 0.79
Pathway-BasedFeature Selection Algorithm for Cancer Microarray Data. Adv Bioinformatics (2010) 0.79
Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway. Breast Cancer Res (2014) 0.78
Blockade of the Hedgehog pathway downregulates estrogen receptor alpha signaling in breast cancer cells. Oncotarget (2016) 0.77
Methylation of PTCH1a gene in a subset of gastric cancers. World J Gastroenterol (2009) 0.77
Immunobiology and signaling pathways of cancer stem cells: implication for cancer therapy. Cytotechnology (2014) 0.76
Epithelial and non-epithelial Ptch1 play opposing roles to regulate proliferation and morphogenesis of the mouse mammary gland. Development (2017) 0.75
New paradigms for the Hedgehog signaling network in mammary gland development and breast Cancer. Biochim Biophys Acta (2017) 0.75
Downregulation of the hedgehog receptor PTCH1 in colorectal serrated adenocarcinomas is not caused by PTCH1 mutations. Virchows Arch (2011) 0.75
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
The status of the world's land and marine mammals: diversity, threat, and knowledge. Science (2008) 8.03
The impact of conservation on the status of the world's vertebrates. Science (2010) 6.71
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet (2007) 4.52
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J (2005) 4.36
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Improved survival in women with BRCA-associated ovarian carcinoma. Cancer (2003) 3.96
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature (2009) 3.80
Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res (2002) 3.64
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol (2010) 3.54
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res (2003) 3.30
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 3.05
The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell (2006) 2.71
Effect of obesity on survival in epithelial ovarian cancer. Cancer (2006) 2.52
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet (2010) 2.47
Is the easier way ever the better way? J Clin Oncol (2011) 2.41
Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med (2009) 2.39
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis (2009) 2.34
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol (2011) 2.33
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood (2007) 2.31
Devastating decline of forest elephants in central Africa. PLoS One (2013) 2.28
Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol (2004) 2.25
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol (2007) 2.20
Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med (2011) 2.16
The SET domain protein Metnase mediates foreign DNA integration and links integration to nonhomologous end-joining repair. Proc Natl Acad Sci U S A (2005) 2.15
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet (2013) 2.14
Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Gynecol Oncol (2009) 2.11
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene (2005) 2.06
Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med (2009) 2.04
Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood (2002) 2.03
Differentiation therapy of leukemia: 3 decades of development. Blood (2009) 2.02
Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood (2004) 1.99
Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol (2004) 1.96
Methylation of histone H3 lysine 36 enhances DNA repair by nonhomologous end-joining. Proc Natl Acad Sci U S A (2010) 1.94
Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. Proc Natl Acad Sci U S A (2002) 1.92
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res (2004) 1.85
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood (2012) 1.85
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol (2009) 1.84
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res (2006) 1.82
Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One (2007) 1.79
BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med (2013) 1.79
Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells. Leuk Res (2006) 1.74
Metnase mediates chromosome decatenation in acute leukemia cells. Blood (2009) 1.74
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer (2007) 1.72
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood (2010) 1.70
Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res (2004) 1.68
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol (2006) 1.65
In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies. Int J Cancer (2007) 1.64
C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leuk Res (2002) 1.64
BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol (2005) 1.63
The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1. Blood (2013) 1.62
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood (2002) 1.60
Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. Hum Pathol (2006) 1.60
Methylation analysis of the adenomatous polyposis coli (APC) gene in adult T-cell leukemia/lymphoma. Leuk Res (2005) 1.56
BCL6 is critical for the development of a diverse primary B cell repertoire. J Exp Med (2010) 1.56
High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res (2009) 1.53
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol (2011) 1.53
Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling. J Biol Chem (2007) 1.53
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res (2007) 1.53
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res (2004) 1.50
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood (2003) 1.50
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res (2013) 1.46
Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Cancer Res (2006) 1.45
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol (2005) 1.45
Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res (2009) 1.43
The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol (2004) 1.43
Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol (2012) 1.42
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol (2006) 1.41
Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays. Blood (2003) 1.40
Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res (2004) 1.40
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene (2002) 1.37
Myelodysplastic syndrome. Annu Rev Med (2005) 1.37
A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther (2007) 1.36
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood (2007) 1.36